IntegraGen
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 7.0m | 7.0m | 8.3m | 9.0m | 11.3m | 13.2m | 12.5m |
| % growth | 17 % | - | 18 % | 8 % | 26 % | 16 % | (5 %) |
| EBITDA | - | - | (<1m) | (<1m) | <1m | <1m | <1m |
| % EBITDA margin | - | - | (1 %) | - | 1 % | 1 % | 1 % |
| Profit | - | - | (<1m) | (<1m) | <1m | (<1m) | (<1m) |
| % profit margin | - | - | (3 %) | (4 %) | - | - | (1 %) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
€8.0m | Series B | ||
€2.0m | Early VC | ||
N/A | Seed | ||
$2.4m | Early VC | ||
| Total Funding | €12.2m | ||
Related Content
Recent News about IntegraGen
EditIntegraGen specializes in genome analysis and the development of molecular diagnostic tests, focusing on oncology and autism. The company operates in the healthcare and biotechnology sectors, serving clinical and research laboratories. IntegraGen's business model revolves around providing genomic services, including high throughput sequencing and bioinformatics, to help researchers and clinicians analyze genomic data. The company generates revenue through the commercialization of its molecular diagnostic tests and genomic services. By identifying novel genetic biomarkers, IntegraGen aims to translate molecular research into clinical practice, aiding in treatment decisions and advancing personalized medicine.
Keywords: genome analysis, molecular diagnostics, oncology, autism, high throughput sequencing, bioinformatics, genetic biomarkers, clinical practice, personalized medicine, genomic services.